Navigation Links
Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market
Date:12/10/2008

MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy

NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis' Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge's and Tekturna's tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.

"The future reimbursement outlook for repackaging of individual hypertension agents is not that promising," according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo's Azor."

About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.

About Formulary Forum

Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information in the United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Lisa Osgood                                 Elizabeth Marshall
    HealthLeaders-InterStudy                    Decision Resources, Inc.
    781-296-2606                                781-296-2563
    losgood@hl-isy.com                          emarshall@dresources.com


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
2. More Than 1,600 Positions to be Filled at PharmaDiversity Job Board's eJobFair in September
3. Siemens Healthcare Executives Recognized With New Industry Leadership Positions
4. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
5. Debate Will Feature Clinton-Obama Positions on Health Care Followed by Straw Poll
6. New therapy prevents dangerous side effect for lymphoma patients
7. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
8. Statin Use Doesnt Inhibit Lymphoma Drug Therapy
9. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
10. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
11. Lenalidomide safe as single therapy for elderly CLL patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Memorial Hermann Health System has teamed up with Houston ... a one-of-a-kind experience to pediatric patients at Children,s ... 360-degree video and Google Cardboard, Howard was able to ... the patients and their families an unexpected, and energetically ... video . Memorial Hermann IRONMAN Sports ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology: